Acropolis Investment Management LLC Sells 1,338 Shares of Johnson & Johnson (NYSE:JNJ)

Acropolis Investment Management LLC trimmed its position in Johnson & Johnson (NYSE:JNJ) by 6.1% in the 4th quarter, Holdings Channel reports. The firm owned 20,717 shares of the company’s stock after selling 1,338 shares during the quarter. Acropolis Investment Management LLC’s holdings in Johnson & Johnson were worth $2,996,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Thurston Springer Miller Herd & Titak Inc. boosted its stake in Johnson & Johnson by 35.2% during the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 17,888 shares of the company’s stock valued at $2,587,000 after buying an additional 4,661 shares during the period. Assenagon Asset Management S.A. boosted its position in shares of Johnson & Johnson by 942.2% during the 4th quarter. Assenagon Asset Management S.A. now owns 911,704 shares of the company’s stock valued at $131,851,000 after acquiring an additional 824,228 shares during the last quarter. Board of the Pension Protection Fund purchased a new position in shares of Johnson & Johnson during the fourth quarter worth about $130,000. Allen Mooney & Barnes Investment Advisors LLC increased its position in shares of Johnson & Johnson by 1.3% in the fourth quarter. Allen Mooney & Barnes Investment Advisors LLC now owns 8,283 shares of the company’s stock worth $1,198,000 after purchasing an additional 106 shares during the last quarter. Finally, Fifth Third Wealth Advisors LLC raised its stake in Johnson & Johnson by 9.1% in the fourth quarter. Fifth Third Wealth Advisors LLC now owns 21,575 shares of the company’s stock valued at $3,120,000 after purchasing an additional 1,800 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Johnson & Johnson

In related news, Director Mark A. Weinberger purchased 1,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Down 0.0 %

Shares of NYSE JNJ opened at $144.74 on Thursday. The company has a market cap of $348.48 billion, a price-to-earnings ratio of 20.95, a PEG ratio of 2.52 and a beta of 0.51. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The firm’s fifty day moving average is $149.12 and its 200 day moving average is $156.09. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. During the same period in the prior year, the firm posted $2.66 earnings per share. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. On average, equities research analysts expect that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.43%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 71.78%.

Analyst Ratings Changes

A number of equities analysts have recently commented on JNJ shares. Royal Bank of Canada increased their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday, October 16th. StockNews.com downgraded Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 7th. Bank of America reiterated a “neutral” rating and issued a $166.00 price objective on shares of Johnson & Johnson in a report on Tuesday, December 10th. Wolfe Research started coverage on Johnson & Johnson in a research report on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price for the company. Finally, Wells Fargo & Company increased their price target on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Seven investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $174.71.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.